CClinicalTrials.gg
Status unknownNCT05009186Updated Aug 17, 2021

Changing of Prostate Specific Antigen Value in Patients With Covid-19

An interventional study of PSA value in Covid19 and Prostate Specific Antigen, sponsored by Saglik Bilimleri Universitesi. Status unknown at 1 site in Turkey. Open to male participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-17.

Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Apr 2020, registered Aug 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
45 Years to 70 Years
Sex
Male
01

Study summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19. In this study, we aimed to evaluate changing of PSA value in patients with Covid-19.

Read the detailed description

Patients with positive PCR test results were included in the study. The age of the patient and urea, leukocyte, hemoglobin, platelet, urea, and creatinine values of the patients were recorded. Urinalysis and urine culture were taken from all patients. Acute phase reactants such as sedimentation, C-reaktif protein (CRP), ferritin, and fibrinogen were measured both at the time the patients applied and three weeks after the patient recovered. PSA and free PSA were also measured in the same way. Patients whose symptoms improved and the PCR test result was negative were considered as recovered.

02

Conditions studied

  • Covid19
  • Prostate Specific Antigen

Browse trials for

Keywords

  • Covid-19
  • Prostate cancer
  • Prostate Specific Antigen
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 4,099 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Saglik Bilimleri Universitesi is the lead sponsor of 430 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Male patients (>45 and \<70 years of age) positive PCR test results were included in the study

Exclusion criteria

Exclusion Criteria:

  • The patients \<45 and >70 years of age who described lower urinary tract symptoms who had urinary tract infection who a history of prostate biopsy and previous high level of PSA who history of prostatitis were excluded.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Covid-19 group

    We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test

    Other: PSA value

Interventions

  • OtherPSA value

    We measure PSA value during and after covid-19 infection

06

What researchers measure

Primary outcomes

  1. PSA value

    prostate specific antigen

    Time frame: 2 months

Secondary outcomes

  1. Ferritin, CRP

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
  • Omer Gokhan Doluoglu
    Ankara, Altindag 06100, Turkey
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05009186
Lead sponsor
Saglik Bilimleri Universitesi
Responsible party
Omer Gokhan Doluoglu (Ankara Training and Research Hospital, Saglik Bilimleri Universitesi) — Principal investigator
First posted
Aug 17, 2021
Start date
Apr 1, 2020
Primary completion
Oct 1, 2021 (estimated)
Completion
Oct 1, 2021 (estimated)
Last update
Aug 17, 2021

Study contacts

Omer G Doluoglu, Associate Professor
Contact
drdoluoglu@yahoo.com.tr
+905332157809
Omer G Doluoglu, Associate Professor
principal investigator · Ankara Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion